Closing the Loop in the Management of Type 1 Diabetes

Numerous challenges afflict patients with type 1 diabetes (T1D) throughout their disease journey. How can newer, more innovative management approaches help patients overcome these challenges?

This episode discusses the challenges that regularly burden patients with T1D, and how recent technological breakthroughs, such as automated insulin pumps and continuous glucose monitoring (CGM), have been transformative in diabetes management.

Our host, Dr. Ronald Goldenberg, takes a deeper look into this topic with Dr. Bruce Perkins, Professor, Endocrinologist, Epidemiologist, and Clinician Scientist in the Faculty of Medicine and the Institute for Health Policy Management and Evaluation at the University of Toronto, and Director of Leadership at the Sinai Centre for Diabetes. Together, they provide practical advice for patients and their healthcare team in managing T1D and discuss emerging developments that have the potential to shift the treatment paradigm in diabetes care.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Ronald Goldenberg:

• Direct financial relationship including receipt of honoraria: Abbott, Agora, Amgen, Antibody, AstraZeneca, Bayer, Boehringer Ingelheim, CCRN, CMSKTRG, Eli Lilly, EOCI, HIT Global, HLS, Inceptus, Janssen, LiV, Master Clinician Alliance, MD Briefcase, Merck, Mylan, Novo Nordisk, Sanofi, Script Medical, Servier, STA, Takeda, Toronto Knowledge Translation Working Group, Unik, Valeant. Membership on advisory boards or speakers’ bureaus: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, HLS, Janssen, Merck, Novo Nordisk, Sanofi. Funded grants, research or clinical trials: Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, Sanofi. 

Dr. Bruce Perkins:

• Direct financial relationship including receipt of honoraria: Novo Nordisk, Sanofi, Abbott, Insulet, Medtronic. Membership on advisory boards: Abbott, Insulet, Novo Nordisk, Sanofi, Vertex. Funded grants, research, or clinical trials: Bank of Montreal, Novo Nordisk. Patent on a drug, product, or device: Boehringer Ingelheim.

MAT-CA-2300841